AgeneBio starts enrolling patients in third phase of testing cognitive impairment do to AD

AgeneBio  has enrolled its first out of 830 patient in a Phase 3 clinical trial of its investigational medication AGB101, to treat amnestic Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD). 

“We are very excited to have commenced the next phase of development on this novel approach to addressing the looming global public health crisis presented by Alzheimer’s Disease,” said Richard Mohs, Principal Investigator on AgeneBio’s HOPE4MCI clinical trial. “We have been extremely encouraged by the number of people who have expressed interest in participating in this trial.”

Accumulated scientific evidence in the field has demonstrated that neural overactivity drives both amyloid and tau pathophysiology in the brain. The HOPE4MCI study builds on an earlier Phase 2 clinical trial that evaluated the efficacy of AGB101 on reducing hippocampal overactivity and on improving episodic memory, the earliest memory impairment in MCI due to AD. Cognitive and functional efficacy in the HOPE4MCI study will be measured by the Clinical Dementia Ratings Scale – Sum of Boxes (CDR-SB) (primary endpoint), Mini Mental State Exam and Functional Activities Questionnaire (MMSE, FAQ).

“We are pleased to be at the forefront of a new direction in Alzheimer’s Disease research moving beyond amyloid directed therapeutics to target the neuronal overactivity that drives downstream pathology and memory impairment” said Sharon Rosenzweig-Lipson, Vice President of Research and Development for AgeneBio. “Based on our Phase 2 findings, we are excited about the potential for this novel therapy to provide hope for millions of people who suffer from amnestic mild cognitive impairment due to Alzheimer’s Disease with no approved treatment options.”